During his 36-year career at Fred Hutch Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that causes AIDS. He and Fred Hutch evolutionary biologist Harmit ...

On June 5, 1981, the U.S. Centers for Disease Control and Prevention's weekly Morbidity and Mortality Report noted an unusual cluster of a particular lung condition found in five previously healthy ...

The conference emphasized advancements in HIV pathogenesis, persistence, and gene therapy, alongside policy and drug use intersections. Lenacapavir was found safe in adolescents, offering new insights ...

Is a cure for HIV in sight? Since the virus that causes AIDS was identified over 40 years ago, finding a cure has been the holy grail of HIV research and the army of scientists conducting it. While ...

Please provide your email address to receive an email when new articles are posted on . Previous studies have shown that DOR/ISL was noninferior to continuing current HIV therapies At 48 weeks, 91.8% ...

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...

As someone who has spent many years studying and responding to viral threats, I’m deeply concerned that we face an unprepared future again. Significant cutbacks in medical science funding, especially ...

ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire-- GeoVax Labs, Inc. (GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...

Vaccine development remains central to reducing incident HIV globally, particularly where long-acting PrEP access is limited, with therapeutic and preventive approaches advancing in parallel.

The U.S. Food and Drug Administration has approved Merck's once-daily, oral, combination regimen for HIV infections, the ...